5 YEARS IN THE MAKING, TARGETED NATIONAL LUNG CANCER SCREENING PROGRAM COMMENCES IN 2025 Lung Foundation Australia CEO talks about opportunity to treat patients presenting at early stage instead of late stage
Australian Health Journal SEGMENT
Filmed in Adelaide | February 2025
INTERVIEWED
Mark Brooke, Chief Executive Officer
Lung Foundation Australia
In February 2025, Australian Health Journal spoke with Mark Brooke, Chief Executive Officer of Lung Foundation Australia, at the 10th Australian Lung Cancer Conference in Adelaide, on the upcoming commencement of the National Lung Cancer Screening Program (NLCSP)
The conference theme, Evolution and Revolution in Lung Cancer, was chosen in recognition of the historic significance of 2025. Mr Brooke emphasised the importance of the National Lung Cancer Screening Program, which is set to begin on July 1st.
The Australian Government’s $267 million investment in the National Lung Cancer Screening Program aims to vastly improve lung cancer detection, treatment, and survivorship. When launched it will be Australia’s first new screening program in over 20 years.
Following a request from the Australian Government, Cancer Australia undertook an enquiry into lung cancer screening, publishing a report that informed the development of the NLCSP.
As the health peak advisory body to the Department of Health and Aged Care, the Lung Foundation aims to amplify the lived experiences of patients within this program. After nearly five years of preparation, the initiative is a crucial step in moving lung cancer diagnoses from late stages (three and four) to early stages (one and two), significantly improving patient care.
Mr Brooke expressed optimism that the timing for this screening program is ideal for Australia, given that lung cancer is the nation’s leading cancer killer. The program’s implementation is particularly challenging because it integrates with General Practice, requiring collaboration from healthcare professionals. While acknowledging potential hurdles, Mr Brooke is confident that the organisation and preparation for the program are well on track.
The program specifically addresses the needs of priority populations, including Aboriginal and Torres Strait Islander communities, who are disproportionately affected by lung cancer. Efforts have been made to provide culturally safe experiences and mobile CT services through partnerships with organisations like Heart of Australia, ensuring access for rural and remote populations.
Over the past five years, the Lung Foundation has collaborated with state governments to support the role of specialist lung cancer nurses. This initiative has proven to enhance timely care and improve patient pathways, ultimately striving for better outcomes in lung cancer treatment.
-
Still seeking outcomes after 6th Stoma Appliance Scheme Schedule Review
50,000 Australians have undergone the trauma and challenge of having a stoma inserted. Whilst the Australian Government invests in the appliances and products they need through the Stoma Appliance Scheme (SAS), this list is dated and doesn’t include as many of the products available in other countries. A new report commissioned by the Stoma Industry Association (SIA) shows Australia lagging countries such as the United Kingdom, Canada and Spain in supporting ostomates (people with a stoma).
-
HIGHLIGHTS Consumers and communities as agents of health care change and improvement
Policymakers, health administrators and clinicians must learn and embrace new ways to harness the transformative role consumers, community members and carers can play. Conversely, consumers and communities need support, capability and capacity to engage as equals in policy, research, program and service design. This is necessary if are to be less technocratic and realise the vision where all members of society can live the best life possible.
-
Imperatives for women diagnosed with ovarian cancer
Professor Clare Scott, a pioneering clinician scientist at the Walter and Eliza Hall Institute of Medical Research in Melbourne, also serves as a medical oncologist at Peter MacCallum Cancer Centre, the Royal Melbourne Hospital, and the Royal Women’s Hospital.
Her comprehensive training in medical oncology has fuelled her specialisation in gynaecological cancer, combining rigorous research with clinical trials to improve patient outcomes. With over a decade of involvement in ANZGOG, Australia’s foremost gynaecologic cancer research organisation, she is deeply committed to advancing research and saving lives.
